Ovarian hyperthecosis in a 62-year-old woman presenting with hyperandrogenism and elevated testosterone
DOI:
https://doi.org/10.34117/bjdv12n1-009Keywords:
hyperandrogenism, postmenopause, ovary, hirsutism, ovarian hyperthecosisAbstract
Ovarian hyperthecosis is a rare cause of hyperandrogenism in postmenopausal women, characterized by proliferation of luteinized stromal cells and excessive androgen production. We report in our article the case of a 62-year-old woman with progressive hirsutism, androgenetic alopecia, and deepening of the voice, associated with markedly elevated testosterone levels. Imaging studies revealed bilateral ovarian enlargement with stromal hyperplasia. The patient underwent bilateral oophorectomy, and histopathology confirmed ovarian hyperthecosis. Clinical improvement and hormonal normalization were observed postoperatively. Early diagnosis and surgical management of ovarian hyperthecosis lead to substantial improvement of symptoms. This condition should be considered in the differential diagnosis of hyperandrogenism in postmenopausal women.
References
HIRSCHBERG AL. Approach to investigation of hyperandrogenism in a postmenopausal woman. J Clin Endocrinol Metab. 2023;108(5):1243–53.
YOUSAF S, NIZAR R, JOHN L, SIMPSON A. A case of ovarian hyperthecosis in a postmenopausal woman. JCEM Case Rep. 2023;1(6):luad148.
HAROON S, ADNAN HA. Stromal hyperplasia and hyperthecosis. PathologyOutlines.com. 2024.
KALTSAS GA, GROSSMAN AB. The clinical features and management of ovarian hyperthecosis. Best Pract Res Clin Endocrinol Metab. 2018;32(4):391–403.
SINGH S, TALWAR P. Ovarian hyperthecosis: A diagnostic challenge. J Obstet Gynaecol Res. 2020;46(3):385–92.
PASCHOU SA, CHRISTAKOU C. Management of ovarian hyperthecosis: clinical outcomes after bilateral oophorectomy. Endocr Rev. 2019;40(5):1286–94.
BROWN JE, SANTEN RJ. Therapeutic approaches to ovarian hyperthecosis: limited role of medical therapy. Clin Endocrinol (Oxf). 2017;87(3):253–60.
FURTADO C, et al. Severe postmenopausal hyperandrogenism due to ovarian hyperthecosis: case report and literature review. Endocr Pract. 2021;27(5):490–4.
ELHASSAN YS, et al. Clinical and biochemical characteristics of women with hyperandrogenism: ovarian and adrenal sources. J Clin Endocrinol Metab. 2006;91(10):3853–60.
EHRMANN DA. Medical management of hyperandrogenism in women. N Engl J Med. 2005;352:1233-1234.
MCDERMOTT EM, et al. Ovarian hyperthecosis: diagnosis and management in postmenopausal women. Clin Endocrinol (Oxf). 2017;86(3):339–46.
WIERMAN ME, et al. Androgen therapy in women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(10):3489–3510.
DAVIS SR, BABER R. Testosterone therapy in women: myths and misconceptions. Climacteric. 2019;22(3):229–234.
POPE HG JR, WOOD RI, ROGOL A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
